

b.) Remarks

Claims 1-3 have been amended in order to recite the present invention with the specificity required by statute. Additionally, withdrawn claims 4-11 are cancelled in order to reduce the issues and expedite prosecution. No new matter has been added.

Claim 3 is not rejected over the prior art and so recites unobvious and patentable subject matter, e.g., is objected to solely as depending upon a rejected base claim. Claim 3 has, accordingly, been rewritten in independent form. The Examiner's assistance in expediting the prosecution of this application by examining separately the subject matter of Applicants' dependent claims is gratefully acknowledged.

Claims 1-2 are rejected under 35 U.S.C. §102(b) as being anticipated by U.S. Patent No. 6,599,605. The '605 patent is relied upon as disclosing the compound noted at page 3 of the Office Action (see Example 1 at column 8). In response, Applicants have above restricted the scope of claim 1 so as to patentably distinguish the prior art.

In view of the above amendments and remarks, Applicants submit that all of the Examiner's concerns are now overcome and the claims are now in allowable condition. Accordingly, reconsideration and allowance of this application is earnestly solicited.

Claims 1-3 remain presented for continued prosecution.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

/Lawrence S. Perry/
Lawrence S. Perry
Attorney for Applicants
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

LSP\ac

FCHS_WS 2741655_1.DOC